Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Menstruating and has cycles between 21 and 35 days~* Meets DSM-IV criteria for PMDD~* Experienced symptoms of PMDD in at least 9 of 12 menstrual cycles within 1 year of study entry~* Willing to use an effective form of birth control throughout the study~Exclusion Criteria:~* Meets MINI DSM-IV criteria for major depressive episode, substance abuse, bulimia nervosa, anorexia, bipolar disorder, or a psychotic disorder, such as schizophrenia or schizoaffective disorder, within 6 months of study entry~* Meets MINI DSM-IV criteria for a substance dependence disorder within 12 months of study entry~* Shows follicular phase symptoms consistent with a diagnosis of major depression~* Shows symptoms consistent with bipolar disorder~* Diagnosed with a severe, clinically significant co-existing condition that may prevent study participation~* Suicidal~* Taking ongoing antidepressant or other psychotropic medication~* History of hypersensitivity or an adverse reaction to sertraline~* Pregnant or breastfeeding~* Currently undergoing treatment with a depot hormonal preparation or any other medication that would lead to a lack of menses or markedly irregular menses~* Using a hormonal contraceptive pill or hormonal device within 6 months of study entry~* Taking a hormonal contraceptive pill that includes 20 micrograms of ethinyl estradiol and 3 micrograms of drospirenone~* Has been in individual psychotherapy or individual counseling for 3 months or less at study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Sertraline (Type: EXPERIMENTAL): Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will take similar looking placebo during the symptomatic period.

Based on this trial design, predict the completion outcome and termination type (if applicable).